文献速递炎症性肠病

免疫球蛋白G糖基化与炎症性肠病临床特征相关

Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases.
PubMed 文献 · Gastroenterology · 2018-01-06

该研究分析了3441份血浆样本,来自意大利和美国的两个独立队列,包含克罗恩病(CD)和溃疡性结肠炎(UC)患者及健康对照。采用液相色谱-质谱联用分析IgG Fc糖基化,发现CD和UC患者IgG半乳糖化水平低于对照,且与疾病严重程度和手术需求相关。

要点

  • CD和UC患者IgG半乳糖化水平均低于健康对照。
  • CD患者IgG岩藻糖化升高,而UC患者降低。
  • 半乳糖化降低与CD或UC更严重及UC需手术相关。

核心结论

  • 在回顾性分析中,IgG Fc糖基化水平与CD和UC疾病状态及其临床特征相关。

研究设计与样本

  • 回顾性分析,纳入两个独立队列共3441份血浆样本:CD患者874例(意大利)和391例(美国),UC患者1056例(意大利)和253例(美国),健康对照427例(意大利)和440例(美国);采用液相色谱-质谱联用分析IgG Fc糖基化,使用逻辑回归模型(年龄和性别为协变量)。

主要发现

  • CD患者IgG1半乳糖化OR为0.59(95%CI 0.51-0.69),UC患者为0.81(95%CI 0.71-0.92),均低于对照。
  • CD患者较对照IgG1岩藻糖化OR为1.27(95%CI 1.12-1.44),UC患者较对照IgG23岩藻糖化OR为0.72(95%CI 0.63-0.82)。
  • UC患者需手术者较对照IgG1半乳糖化OR为0.69(95%CI 0.54-0.89),CD患者需手术者较对照IgG23半乳糖化OR为0.78(95%CI 0.66-0.91)。

关键数值与推荐

  • CD患者IgG1半乳糖化OR为0.59(95%CI 0.51-0.69),UC患者为0.81(95%CI 0.71-0.92)。
  • CD患者较对照IgG1岩藻糖化OR为1.27(95%CI 1.12-1.44),UC患者较对照IgG23岩藻糖化OR为0.72(95%CI 0.63-0.82)。
  • UC患者需手术者较对照IgG1半乳糖化OR为0.69(95%CI 0.54-0.89),CD患者需手术者较对照IgG23半乳糖化OR为0.78(95%CI 0.66-0.91)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Causes of inflammatory bowel diseases are not well understood and the most prominent forms, Crohn's disease (CD) and ulcerative colitis (UC), are sometimes hard to distinguish. Glycosylation of IgG has been associated with CD and UC. IgG Fc-glycosylation affects IgG effector functions. We evaluated changes in IgG Fc-glycosylation associated with UC and CD, as well as with disease characteristics in different patient groups. METHODS: We analyzed 3441 plasma samples obtained from 2 independent cohorts of patients with CD (874 patients from Italy and 391 from the United States) or UC (1056 from Italy and 253 from the US and healthy individuals [controls]; 427 in Italy and 440 from the United States). IgG Fc-glycosylation (tryptic glycopeptides) was analyzed by liquid chromatography coupled to mass spectrometry. We analyzed associations between disease status (UC vs controls, CD vs controls, and UC vs CD) and glycopeptide traits, and associations between clinical characteristics and glycopeptide traits, using a logistic regression model with age and sex included as covariates. RESULTS: Patients with CD or UC had lower levels of IgG galactosylation than controls. For example, the odds ratio (OR) for IgG1 galactosylation in patients with CD was 0.59 (95% confidence interval [CI], 0.51-0.69) and for patients with UC was 0.81 (95% CI, 0.71-0.92). Fucosylation of IgG was increased in patients with CD vs controls (for IgG1: OR, 1.27; 95% CI, 1.12-1.44), but decreased in patients with UC vs controls (for IgG23: OR, 0.72; 95% CI, 0.63-0.82). Decreased galactosylation associated with more severe CD or UC, including the need for surgery in patients with UC vs controls (for IgG1: OR, 0.69; 95% CI, 0.54-0.89) and in patients with CD vs controls (for IgG23: OR, 0.78; 95% CI, 0.66-0.91). CONCLUSIONS: In a retrospective analysis of plasma samples from patients with CD or UC, we associated levels of IgG Fc-glycosylation with disease (compared to controls) and its clinical features. These findings could increase our understanding of mechanisms of CD and UC pathogenesis and be used to develop diagnostics or guide treatment.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Šimurina M, de Haan N, Vučković F, et al. Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology. 2018. PMID: 29309774. doi:10.1053/j.gastro.2018.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。